2nd Quarter - Report

HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) for HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)

Firm
Client
Income
—
Expenses
$1,090,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 19 "Lower Costs, More Cures Act of 2021," all provisions. Issues pertaining to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.

Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.

LobbyistCovered position, as disclosed
JORDAN CHAPMAN —
BRENTON J FISK —
ELI KOGAN —
MATT MCMURRAY —
BETH RADA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6963 (118th), H.R. 830 (118th), H.R. 5376 (118th), H.R. 2620 (118th), H.R. 3173 (118th), H.R. 19 (118th)

Taxation/Internal Revenue Code TAX

Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.

Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.

LobbyistCovered position, as disclosed
BRENTON J FISK —
ELI KOGAN —
BETH RADA —

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.